Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pfizer Corporation Hong Kong Limited - Optimising treatment in ALK+ NSCLC: Debate and Ongoing Conversations

Expert debate: Management options in ALK+ NSCLC

Date

19 Nov 2021

Session

Pfizer Corporation Hong Kong Limited - Optimising treatment in ALK+ NSCLC: Debate and Ongoing Conversations

Presenters

Alona Zer

Authors

S.I. Ou1, A. Zer2

Author affiliations

  • 1 Medicine Department, UCI Health Chao Family Comprehensive Cancer Center, 92868 - Orange/US
  • 2 Medical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 4941492 - Petah Tikva/IL
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.